The pharmaceuticals company Glenmark Pharma Ltd introduce medicine for the time with the combination of Teneligliptin (20mg) and Dapagliflozin (5mg/10mg) for the treatment of adult patients with type two diabetes, especially the ones with comorbidities.
- DPIIT Teams Up With Startup Policy Forum
- Rural Poverty Slips Below 5% for FY24
- Capital Infra Trust InvIT IPO Preview: Latest capital Infra GMP, Lot, Price & Key Dates
- Smartworks Leases a New Office Space in Gurugram
- Indian Railway Finance Shares Surge 3% on Signing an MoU with REMC
‘Zita D’ which contains Teneligliptin (20mg) andDapagliflozin (5 mg/10 mg). This medicine can be consumed by the patient once a day daily as per prescription, which helps to improve glycemic control and prevent complications in adult patients with type two diabetes, especially the ones with comorbidities, as per the statement said.
